Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)

Hoffmann-La Roche91 enrolled

Overview

This study is a prospective, cross-sectional survey to be administered to real patients in remission from DLBCL using a 15-minute postal or online survey. The project is designed to describe the impact of DLBCL remission on health utility and quality of life. Data collection will occur over a 4-month period.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diffuse Large B-Cell Lymphoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults greater than or equal to (\>/=) 18 years of age * Diagnosis of DLBCL and currently in first remission * Prior drug treatment for DLBCL Exclusion Criteria: * Receiving active treatment for DLBCL * Relapsed following any treatment for DLBCL

Locations (1)

PH Associates - an OPen Health Company

Marlow, United Kingdom

Outcomes

Primary Outcomes

Health-Related Quality of Life According to European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Score

Time frame: Up to 4 months of data collection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.